Premium
Cover Picture: Design and Synthesis of Highly Active Peroxisome Proliferator‐Activated Receptor (PPAR) β/δ Inverse Agonists with Prolonged Cellular Activity (ChemMedChem 5/2016)
Author(s) -
Toth Philipp M.,
Lieber Sonja,
Scheer Frithjof M.,
Schumann Tim,
Schober Yvonne,
Nockher Wolfgang A.,
Adhikary Till,
MüllerBrüsselbach Sabine,
Müller Rolf,
Diederich Wibke E.
Publication year - 2016
Publication title -
chemmedchem
Language(s) - English
Resource type - Reports
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.201600106
Subject(s) - chemistry , inverse agonist , peroxisome proliferator activated receptor , peroxisome , stereochemistry , agonist , receptor , biochemistry
The front cover picture shows the development of the inverse PPARβ/δ agonist methyl 3‐( N ‐(2‐(2‐ethoxyethoxy)‐4‐(hexylamino)phenyl)sulfamoyl)thiophene‐2‐carboxylate (PT‐S264, 9u , shown centered). Inspired by the X‐structure of the fatty acid eicosapentaenoic acid in complex with the PPARβ/δ ligand‐binding domain, we envisioned that Y‐shaped ligands (orange Y) would most likely better mimic the binding cleft, thus leading to a series of compounds displaying increased potency. To optimize the solubility of the compounds with respect to assay conditions, the introduction of an additional oxygen (orange O) in the newly incorporated side chain finally led to 9u , one of the most potent inverse PPARβ/δ agonists described so far. Furthermore, 9u displayed prolonged cellular activity and, moreover, biologically relevant plasma concentrations in mice could be achieved. More information can be found in the Full Paper by Wibke E. Diederich et al. on page 488 in Issue 5, 2016 (DOI: 10.1002/cmdc.201500594).